Identification of Three Novel LRRK2 Mutations associated with Parkinson's Disease in a Calabrian Population

被引:6
|
作者
Anfossi, Maria [1 ]
Colao, Rosanna [1 ]
Gallo, Maura [1 ]
Bernardi, Livia [1 ]
Conidi, M. Elena [1 ]
Frangipane, Francesca [1 ]
Vasso, Franca [1 ]
Puccio, Gianfranco [1 ]
Clodomiro, Alessandra [1 ]
Mirabelli, Maria [1 ]
Curcio, Sabrina A. M. [1 ]
Torchia, Giusi [1 ]
Smirne, Nicoletta [1 ]
Di Lorenzo, Raffaele [1 ]
Maletta, Raffaele [1 ]
Bruni, Amalia C. [1 ]
机构
[1] Azienda Sanit Prov Catanzaro, Ctr Reg Neurogenet, I-8046 Lamezia Terme, CZ, Italy
关键词
Dementia; frequency mutations; genetics association; LRRK2; neurodegenerative disease; Parkinson's disease; G2019S MUTATION; CLINICAL-FEATURES; SPANISH PATIENTS; GENE; FREQUENCY; CARRIERS; PHENOTYPE; DIAGNOSIS; DEMENTIA;
D O I
10.3233/JAD-130689
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: LRRK2 mutations are common in familial and sporadic Parkinson's disease (PD) cases. Objective: We present a screening of the most frequently mutated exons of LRRK2 in Calabrian population. Methods: Eighty-eight PD patients diagnosed according to standard criteria, underwent screening for LRRK2 mutations in exons 19, 21, 24, 25, 27, 29, 31, 32, 33, 35, 38, 40, 41, and 48. Results: Eight LRRK2 variations were identified in nine patients affected by PD, including three novel missense variations (p.Phe1227Leu, p.Gly1520Ala, p.Ile2020Ser) and five previously identified mutations (p.Ala1151Thr, IVS31+ 3A>G, p. Arg1514Gln, p. Gly2019Ser, p.Thr2356Ile). LRRK2 frequency mutations were approximately 10.2% in all PD patients, 12% in familial, 8% in sporadic cases. The p. Gly2019Ser mutation was found in 2.3% of the total cohort and in 3.2% of sporadic cases. The clinical features of LRRK2-associated with PD in our patients were similar to those of idiopathic PD although most LRRK2 mutated patients presented with bradykinesia instead of tremor; 33.3% developed dementia. Conclusions: We identified three novel LRRK2 mutations and reported a higher frequency in Calabria compared to previously reported data possibly due to the relative genetic isolation of the Calabrian population. These findings contribute to the understanding of the role of LRKK2 variations in PD and provide additional genetic insight into this disease.
引用
收藏
页码:351 / 357
页数:7
相关论文
共 50 条
  • [41] LRRK2 kinase in Parkinson's disease
    Alessi, Dario R.
    Sammler, Esther
    SCIENCE, 2018, 360 (6384) : 36 - 37
  • [42] Function of LRRK2 in Parkinson's Disease
    Zhu Fei-Zhou
    Xia Kun
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2010, 37 (10) : 1059 - 1066
  • [43] LRRK2 pathobiology in Parkinson's disease
    Martin, Ian
    Kim, Jungwoo Wren
    Dawson, Valina L.
    Dawson, Ted M.
    JOURNAL OF NEUROCHEMISTRY, 2014, 131 (05) : 554 - 565
  • [44] LRRK2 and Proteostasis in Parkinson's Disease
    Perez-Carrion, Maria Dolores
    Posadas, Inmaculada
    Solera, Javier
    Cena, Valentin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
  • [45] LRRK2 and idiopathic Parkinson's disease
    Rocha, Emily M.
    Keeney, Matthew T.
    Di Maio, Roberto
    De Miranda, Briana R.
    Greenamyre, J. Timothy
    TRENDS IN NEUROSCIENCES, 2022, 45 (03) : 224 - 236
  • [46] LRRK2 and GBA Founder Mutations and their Interactions in Parkinson's disease (PD)
    Kmiecik, M.
    Riboldi, G.
    Schneider, R.
    Stagaman, K.
    Sonmez, T. Filshtein
    Guan, A.
    Wetzel, M.
    Fontanillas, P.
    Holmes, M.
    Aslibekyan, S.
    Norcliffe-Kaufmann, L.
    MOVEMENT DISORDERS, 2024, 39 : S761 - S761
  • [47] Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations
    Macias-Garcia, Daniel
    Perinan, Maria Teresa
    Munoz-Delgado, Laura
    Jesus, Silvia
    Jimenez-Jaraba, Maria Valle
    Buiza-Rueda, Dolores
    Bonilla-Toribio, Marta
    Adarmes-Gomez, Astrid
    Carrillo, Fatima
    Gomez-Garre, Pilar
    Mir, Pablo
    MOVEMENT DISORDERS, 2022, 37 (01) : 225 - 227
  • [48] Targeting LRRK2 in Parkinson's disease
    Xiao, Bin
    Tan, Eng-King
    CELL REPORTS MEDICINE, 2022, 3 (10)
  • [49] Alpha-synuclein oligomers in Parkinson's disease with LRRK2 mutations
    Sekiya, H.
    Hashimoto, Y.
    Takata, M.
    Koga, S.
    Hasegawa, K.
    Kowa, H.
    Toda, T.
    Wszolek, Z.
    Dickson, D.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 514 - 514
  • [50] Association Between Cancer and LRRK2 Mutations in Parkinson's Disease Patients
    Inzelberg, R.
    Hassin-Baer, S.
    Cohen, O. S.
    Aharon-Peretz, J.
    Schlesinger, I.
    Gershoni, R.
    Djaldetti, R.
    Schechtman, E.
    Friedman, E.
    MOVEMENT DISORDERS, 2010, 25 : S648 - S649